pharma · Asthma · Respiratory Syncytial Virus Infections
GSK Glaxo Smith
GlaxoSmithKline
GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
- Employees
- 30
- Programs
- 205
- Drugs
- 194
- Patents
- 0
217102
Phase 3 · small molecule · Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
217102 for Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Internal code 217102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy
- Status
- active
- Trials
- 1